Skip to main content
. 2021 Feb 25;11:4547. doi: 10.1038/s41598-021-84225-6

Table 4.

Efficacy analysis in 36 patients.

Phase Acute % (CI) Delayed % (CI) Overall % (CI)
No vomiting 100 (90–100) 100 (90–100) 100 (90–100)
No nausea 97.2 (86–100) 61.1 (45–75) 61.1 (45–75)
No significant nausea 100 (90–100) 94.4 (82–98) 94.4 (82–98)
Complete response 100 (90–100) 86.1 (71–94) 86.1 (71–94)
Complete control 100 (90–100) 86.1 (71–94) 86.1 (71–94)
Total control 97.2 (86–100) 55.6 (40–70) 55.6 (40–70)

CI 95% confidence interval.